Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1997-08-04
1999-11-02
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 189, 514255, 544362, A61K 4900
Patent
active
059764970
ABSTRACT:
Described herein are D4 receptor-selective compounds of the formula: ##STR1## wherein R.sup.1 is selected from H and an acid labile protecting group; and R.sup.2 and R.sup.3 are independently selected from H, radioisotopic halo, loweralkoxy and tri(loweralkyl)tin; and salts, solvates or hydrates thereof.
Also described is the use of these compounds as pharmaceuticals to treat indications for which a dopamine D4 receptor antagonist is indicated. Radiolabeled compounds are useful particularly to image localization of D4 receptor in the human brain, and can therefore aid in the diagnosis of schizophrenia and other medical conditions in which the D4 receptor is implicated.
REFERENCES:
patent: 3362956 (1968-01-01), Archer
patent: 3511841 (1970-05-01), Archer
patent: 5219860 (1993-06-01), Chambers et al.
patent: 5304367 (1994-04-01), Biegon
patent: 5324733 (1994-06-01), Billington et al.
patent: 5372813 (1994-12-01), Mathis, Jr. et al.
patent: 5432177 (1995-07-01), Baker et al.
patent: 5576319 (1996-11-01), Baker et al.
patent: 5622950 (1997-04-01), Baker et al.
Kulagowski et al, J Med Chem, 1996, 39:1941 "3-[[4-4-(Chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor".
Kung et al, Society for Neurosciences Abstracts, vol. 22, Part 2, Abstract No. 330.5, p. 828, presented at the 26th Annual Meeting of the Society for Neurosciences, Nov. 16-21, 1996, Washington, D.C.. "Binding Characteristics of Iodinated Ligands for Dopamine D4 Receptors".
Patel et al, Molecular Pharmacology, 1996, 50:1158-1664 "Identification and Pharmacological Characterization of [.sup.125 I]L-750, 667, a Novel Radioligand for the Dopamine D.sub.4 Receptor".
Chavez-Eng et al, Journal of Chromatography B, 1997, vol. 691, pp. 77-85 "Picogram Determination of a Novel Dopamine D.sub.4 Receptor Antagonist in Human Plasma and Urine by Liquid Chromatography with Atmospheric Pressure Chemical Ionization Tandam Mass Spectrometry".
Kung et al, Life Sciences, 1997, vol. 60, No. 2, pp. 91-100 "Characterization of a Novel Iodinated Ligand, IPMPP, for Human Dopamine D.sub.4 Receptors Expressed in CHO Cells".
Patel et al, Life Science News, Nov. 1996, Issue 21, pp. 21 "[.sup.125 I]L-750, 667, a Novel Radioligand for the Dopamine D.sub.4 Receptor".
Dunn-Dufault Robert
Pollak Alfred
Roe David
Raymond Richard L.
Resolution Pharmaceuticals Inc.
LandOfFree
Dopamine D4 receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dopamine D4 receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine D4 receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2131209